MA46061A - Traitement ascaroside de maladies auto-immunes et inflammatoires - Google Patents

Traitement ascaroside de maladies auto-immunes et inflammatoires

Info

Publication number
MA46061A
MA46061A MA046061A MA46061A MA46061A MA 46061 A MA46061 A MA 46061A MA 046061 A MA046061 A MA 046061A MA 46061 A MA46061 A MA 46061A MA 46061 A MA46061 A MA 46061A
Authority
MA
Morocco
Prior art keywords
ascaroside
autoimmune
treatment
inflammatory diseases
inflammatory
Prior art date
Application number
MA046061A
Other languages
English (en)
Inventor
Andrea Choe
Frank C Schroeder
Paul W Sternberg
Original Assignee
Boyce Thompson Institute For Plant Res
California Inst Of Techn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boyce Thompson Institute For Plant Res, California Inst Of Techn filed Critical Boyce Thompson Institute For Plant Res
Publication of MA46061A publication Critical patent/MA46061A/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56Materials from animals other than mammals
    • A61K35/62Leeches; Worms, e.g. cestodes, tapeworms, nematodes, roundworms, earth worms, ascarids, filarias, hookworms, trichinella or taenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869Interleukin
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA046061A 2016-08-25 2017-08-25 Traitement ascaroside de maladies auto-immunes et inflammatoires MA46061A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662379651P 2016-08-25 2016-08-25

Publications (1)

Publication Number Publication Date
MA46061A true MA46061A (fr) 2019-07-03

Family

ID=61245393

Family Applications (2)

Application Number Title Priority Date Filing Date
MA046061A MA46061A (fr) 2016-08-25 2017-08-25 Traitement ascaroside de maladies auto-immunes et inflammatoires
MA046062A MA46062A (fr) 2016-08-25 2017-08-25 Traitement par ascaroside de l'oesophagite à éosinophiles

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA046062A MA46062A (fr) 2016-08-25 2017-08-25 Traitement par ascaroside de l'oesophagite à éosinophiles

Country Status (5)

Country Link
US (4) US11077151B2 (fr)
EP (2) EP3503904B1 (fr)
CN (1) CN109843309A (fr)
MA (2) MA46061A (fr)
WO (2) WO2018039591A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107417745A (zh) 2011-08-08 2017-12-01 加州理工学院 线虫小分子的应用
WO2018039591A1 (fr) 2016-08-25 2018-03-01 California Institute Of Technology Traitement ascaroside de maladies auto-immunes et inflammatoires
WO2020236621A1 (fr) 2019-05-17 2020-11-26 California Institute Of Technology Dérivés d'ascaroside et procédés d'utilisation
US20220264876A1 (en) * 2019-07-08 2022-08-25 Boyce Thompson Institute For Plant Research, Inc. Compositions and methods for enhancing plant growth
MX2023001492A (es) * 2020-08-06 2023-03-08 Bioverativ Usa Inc Citocinas inflamatorias y fatiga en sujetos con una enfermedad mediada por el complemento.
CN113475629A (zh) * 2021-08-12 2021-10-08 广东省科学院动物研究所 蛔甙在制备提高S.carpocapsae All线虫产量制剂中的应用
CN113575770A (zh) * 2021-08-12 2021-11-02 广东省科学院动物研究所 蛔甙在制备促进S.carpocapsae All感染期线虫恢复发育制剂中的应用
CN113796460B (zh) * 2021-08-19 2023-07-18 云南省烟草公司玉溪市公司 蛔甙在制备促进H.indica LN2感染期线虫恢复发育制剂中的应用
CN113728978A (zh) * 2021-08-19 2021-12-03 云南省烟草公司玉溪市公司 蛔甙在制备H.bacteriophora H06感染期线虫恢复发育制剂中的应用
US20250287946A1 (en) * 2022-04-29 2025-09-18 Ascribe Bioscience Inc. Modified release of ascarosides
AR133343A1 (es) * 2023-07-25 2025-09-17 Ascribe Bioscience Inc Combinaciones de nutrientes vegetales y ascarósidos y métodos para su uso
CN119606992A (zh) * 2024-04-25 2025-03-14 中国科学院动物研究所 蛔甙在制备治疗与肥胖相关的疾病的药物中的用途

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1018396A (en) 1911-08-07 1912-02-20 Oley L Ledington Culvert-mold.
US4172896A (en) 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
GB9217295D0 (en) 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
US5358970A (en) 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
US5541231A (en) 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
GB9315856D0 (en) 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
TW327125B (en) 1994-02-07 1998-02-21 Merck & Co Inc Composition and method for protecting against pine exhausted
WO1996019920A1 (fr) 1994-12-27 1996-07-04 Pfizer Pharmaceuticals Inc. Compositions utilisees pour traiter les infections des arbres par les nematodes
ATE391492T1 (de) 1997-07-29 2008-04-15 Alcon Lab Inc Ophthalmische zusammensetzungen enthaltend galaktomannanpolymere und borat
EP1051167A1 (fr) 1998-01-29 2000-11-15 Sepracor, Inc. Utilisations pharmaceutiques de (-)-bupropion optiquement pur
US6444686B1 (en) 1998-12-18 2002-09-03 Brsitol-Myers Squibb Pharma Company N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
US8889112B2 (en) 1999-09-16 2014-11-18 Ocularis Pharma, Llc Ophthalmic formulations including selective alpha 1 antagonists
DE10163602A1 (de) 2001-12-21 2003-07-10 Alpha Biocare Gmbh Gebaeude 26 Mittel mit Nematoden und Plathelminthen zur Behandlung allergischer Erkrankungen
KR100700884B1 (ko) 2002-11-14 2007-03-29 백융기 약학적으로 유용한 노화 및 스트레스 조절용 신규 페로몬 화합물 및 그 분리정제방법
US6933289B2 (en) 2003-07-01 2005-08-23 Allergan, Inc. Inhibition of irritating side effects associated with use of a topical ophthalmic medication
ES2593113T3 (es) 2003-08-07 2016-12-05 Allergan, Inc. Composiciones para el suministro de agentes terapéuticos en los ojos y métodos para obtener y usar los mismos
US20050059744A1 (en) 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
KR100556335B1 (ko) 2004-02-05 2006-03-03 정만길 6알-(3,6-디데옥시-엘-아라비노-헥소피라노실옥시)헵타노익산, 그 제조방법 및 그를 포함하는 장기휴면 유발효과
AU2005244126B2 (en) 2004-05-11 2011-05-12 Bayer Cropscience Lp Method of controlling termites
DE102006056544A1 (de) 2006-11-29 2008-06-05 Bayer Cropscience Ag Insektizide Wirkstoffkombinationen (Formononetin+Insektizide)
EA200901143A1 (ru) 2007-03-01 2010-04-30 Басф Се Пестицидные активные смеси, включающие аминотиазолиновые соединения
US8318146B1 (en) 2008-02-01 2012-11-27 The United States Of America, As Represented By The Secretary Of Agriculture Ascarosides as nematode sex pheromones
CN104356177A (zh) 2008-02-12 2015-02-18 陶氏益农公司 杀虫组合物
KR20090088496A (ko) 2008-02-15 2009-08-20 연세대학교 산학협력단 6-(3,6-디데옥시-α-L-아라비노-헥소피라노실옥시)헵타노익산 유도체 및 그 제조 방법
US20090264392A1 (en) * 2008-04-21 2009-10-22 Meritage Pharma, Inc. Treating eosinophilic esophagitis
GB0823309D0 (en) 2008-12-19 2009-01-28 Univ Bath Functionalising reagents and their uses
KR101210553B1 (ko) 2010-06-09 2012-12-10 연세대학교 산학협력단 신규한 당지질 유도체 화합물 및 이를 함유하는 혈관평활근세포 이상 증식 억제용 조성물
WO2011163614A2 (fr) * 2010-06-24 2011-12-29 Meritage Pharma, Inc. Méthodes de traitement de l'inflammation œsophagienne
EP2707379A4 (fr) 2011-05-13 2014-10-08 Glycosyn LLC Utilisation de 2'-fucosyllactose, 3-fucosyllactose et lactodifucotétraose purifiés en tant que prébiotiques
US9445596B2 (en) 2011-08-08 2016-09-20 California Institute Of Technology Small molecule compounds for the control of nematodes
CN107417745A (zh) 2011-08-08 2017-12-01 加州理工学院 线虫小分子的应用
WO2013039872A1 (fr) 2011-09-12 2013-03-21 Tufts Medical Center Compositions et procédés pour le traitement de maladies inflammatoires de l'intestin
LT3091029T (lt) * 2011-10-31 2023-02-27 F. Hoffmann-La Roche Ag Anti-il13 antikūno kompozicijos
WO2014151648A1 (fr) 2013-03-15 2014-09-25 Coronado Biosciences, Inc. Traitement d'une maladie auto-immune au moyen de parasites helminthiques
US10136595B2 (en) 2013-03-15 2018-11-27 Boyce Thompson Institute For Plant Research, Inc. Compositions and methods for modulating immunity in plants
CN105263324B (zh) * 2013-03-15 2020-02-11 博伊斯汤普生植物研究所 用于调节植物免疫的组合物和方法
MA41020A (fr) 2014-11-25 2017-10-03 Evelo Biosciences Inc Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome
WO2018039591A1 (fr) 2016-08-25 2018-03-01 California Institute Of Technology Traitement ascaroside de maladies auto-immunes et inflammatoires
WO2020236621A1 (fr) 2019-05-17 2020-11-26 California Institute Of Technology Dérivés d'ascaroside et procédés d'utilisation
US20220409650A1 (en) 2019-06-03 2022-12-29 Holoclara, Inc. Compositions and methods for ascaroside modification of mammalian microbiota

Also Published As

Publication number Publication date
US20220016182A1 (en) 2022-01-20
US20190192578A1 (en) 2019-06-27
EP3503904A1 (fr) 2019-07-03
WO2018039591A1 (fr) 2018-03-01
EP3503904B1 (fr) 2026-01-21
US11077151B2 (en) 2021-08-03
EP3503904C0 (fr) 2026-01-21
US11464810B2 (en) 2022-10-11
EP3503903A4 (fr) 2020-03-25
EP3503904A4 (fr) 2020-03-25
MA46062A (fr) 2019-07-03
WO2018039593A9 (fr) 2018-05-03
EP3503903A1 (fr) 2019-07-03
CN109843309A (zh) 2019-06-04
US20190175663A1 (en) 2019-06-13
US20230026686A1 (en) 2023-01-26
WO2018039593A1 (fr) 2018-03-01

Similar Documents

Publication Publication Date Title
EP3503903A4 (fr) Traitement ascaroside de maladies auto-immunes et inflammatoires
IL262608A (en) Combination treatment of ocular inflammatory disorders and diseases
EP3634442A4 (fr) Méthodes de traitement et de prévention de maladies
SI3240554T1 (sl) Blautia stercosis in wexlerae za uporabo v zdravljenju vnetnih in avtoimunskih bolezni
EP3658139A4 (fr) Méthodes de traitement de maladies hépatiques
EP3373962A4 (fr) Compositions et méthodes de traitement de maladies auto-immunes et de cancers
EP3397149A4 (fr) Cartographie et traitement de tissu
EP3344258A4 (fr) Traitement de maladies auto-immunes et de maladies auto-inflammatoires
EP3390634A4 (fr) Compositions et méthodes pour le traitement de maladies oculaires
EP2983791A4 (fr) Procédés et compositions pour le traitement de maladies auto-immunes
FR25C1031I1 (fr) Traitement de maladies cholestatiques intrahepatiques
IL284125A (en) Quinoline derivatives for use in the treatment of inflammation diseases
EP3273955A4 (fr) Traitement de maladies respiratoires
MA42930A (fr) Traitement de maladies neurodégénératives
EP3458454A4 (fr) Nouveaux découplants mitochondriaux pour le traitement de maladies métaboliques et du cancer
IL269158A (en) Compositions and methods for treating inflammatory diseases
IL262713A (en) Cannabidiol for reducing a steroid dose and treating inflammatory and autoimmune diseases
EP2945616A4 (fr) Traitement de maladies pulmonaires
EP3664789A4 (fr) Méthodes de traitement de maladies et de lésions des nerfs
EP3313417A4 (fr) Méthodes de traitement de troubles auto-immuns et allo-immuns
EP3737363A4 (fr) Méthodes de traitement de maladies inflammatoires chroniques
FR3017298B1 (fr) Conjugues et pro-drogues pour le traitement du cancer et de maladies inflammatoires
MA41462A (fr) Méthode de traitement de maladies
MA53986A (fr) Traitement de maladies neurologiques avec du zilucoplan
EP3727369A4 (fr) Test théragnostique pour le traitement antifongique de maladies inflammatoires